Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Localism & Local Languages Make For Better Medtech Business In Russia And EAEU

Executive Summary

The probability of a postponed entry-in-force of the single Eurasian Economic Union system of medtech regulation has increased over the course of this year, according to speakers at the 2018 Informa KNect 365 Medtech Summit. But the drive for stronger local medtech industries continues, leaving foreign manufacturers with market-access problems to address.

You may also be interested in...



Eurasian Medtech System Still 'Officially Targeting' 2021 Deadline

The mood among various EAEU member states is that the deadline for system adoption should be extended beyond the end of 2021. So far, the authorities have not budged, though progress on system infrastructure continues to be made, according to local regulatory expert Alexey Stepanov.

Medtech Reg Progress In Russia, CIS And Eurasian Union At Operational Level

Various economies of the Commonwealth of Independent States (CIS) and the Eurasian Economic Union (EAEU) are pressing ahead with medtech regulatory changes nationally and/or regionally, which can only be good for the delivery of quality care over the long term. But a question mark still hangs over the official start date of the EAEU medtech regulatory system; a formal postponement may be decided soon.

Russia Seeks To Balance Support For Local Industry With Medtech Coverage

Confidence may be seeping back into the Russian medtech market, but the drive for localization of medtech supplies in a country that is still adjusting to a new national regulatory system is a complication that threatens to disrupt product availability.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122961

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel